EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL

被引：0

作者：

Stephen, Boorjian A.

Vikram, Narayan M.

Viraj, Master A.

Badrinath, Konety R.

Neal, Shore D.

Ashish, Kamat M.

Colin, Dinney P. N.

Trinity, Bivalacqua J.

Max, Kates R.

Jeffrey, Montgomery S.

Seth, Lerner P.

Paul, Crispen L.

Gary, Steinberg D.

Piyush, Agarwal K.

Anne, Schuckman K.

Robert, Svatek S.

Brian, Lane R.

Lawrence, Karsh, I

Marc, Bjurlin A.

Gordon, Brown A.

Yair, Lotan

Brant, Inman A.

Michael, Williams B.

Michael, Cookson S.

Sam, Chang S.

Eric, Kim H.

Alexander, Sankin, I

Michael, O'Donnell A.

Jorn, Jakobsen S.

Kristian, Juul

机构：

[1] Mayo Clin, Dept Urol, Rochester, MN USA

[2] Emory Univ, Dept Urol, Sch Med, Atlanta, GA USA

[3] Univ Minnesota, Dept Urol, Minneapolis, MN USA

[4] Allina Hlth Canc Inst, Minneapolis, MN USA

[5] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA

[7] James Buchanan Brady Urol Inst, Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA

[8] Univ Michigan, Dept Urol, Ann Arbor, MI USA

[9] Baylor Coll Med, Scott Dept Urol, Houston, TX USA

[10] Univ Florida, Dept Urol, Gainesville, FL USA

[11] Rush Univ, Dept Urol, Chicago, IL USA

[12] Univ Chicago, Sect Urol, Dept Surg, Chicago, IL USA

[13] Univ Southern Calif, Inst Urol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[14] Univ Texas Hlth San Antonio, Dept Urol, San Antonio, TX USA

[15] Michigan State Univ, Div Urol, Spectrum Hlth, Coll Human Med, Grand Rapids, MI USA

[16] Urol Ctr Colorado, Denver, CO USA

[17] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[18] Univ N Carolina, Dept Urol, Chapel Hill, NC USA

[19] New Jersey Urol, Bloomfield, NJ USA

[20] Univ Texas Southwestern Med Ctr, Dept Urol, Dallas, TX USA

[21] Duke Univ, Div Urol, Dept Surg, Sch Med, Durham, NC USA

[22] Urol Virginia, Virginia Beach, VA USA

[23] Univ Oklahoma, Dept Urol, Hlth Sci Ctr, Oklahoma City, OK USA

[24] Vanderbilt Univ, Div Urol Oncol, Nashville, TN USA

[25] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[26] Montefiore Med Ctr, Dept Urol, Bronx, NY USA

[27] Univ Iowa, Dept Urol, Iowa City, IA USA

[28] Ferring Pharmaceut A S, Copenhagen, Denmark

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2024年 / 42卷

关键词：

D O I：

10.1016/j.urolonc.2024.01.201

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

164

引用

页码：S70 / S70

页数：1

共 50 条

[31] Participatory care plan for primary care patients with long-term diseases: results after a 36-month follow-up of a randomized controlled trial
Nina Tusa
Ulla Mikkonen
Hannu Kautiainen
Pekka Mäntyselkä
BMC Health Services Research, 25 (1)
[32] Replication Competent Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy in Prostate Cancer: 36-month Follow-Up Data from a Phase I Clinical Trial
Nyati, Shyam
Stricker, Hans
Barton, Kenneth N.
Li, Pin
Elshaikh, Mohamed
Ali, Haythem
Brown, Stephen L.
Hwang, Clara
Peabody, James
Freytag, Svend O.
Movsas, Benjamin
Siddiqui, Farzan
MOLECULAR THERAPY, 2023, 31 (04) : 297 - 297
[33] COMPARISON OF SAFETY AND EFFICACY OF BIPOLAR PLASMAKINETIC TRANSURETHRAL ENUCLEATION AND HOLMIUM LASER ENUCLEATION OF PROSTATE GLAND GREATER THAN 80ML IN PATIENTS: A RANDOMIZED TRIAL WITH 36-MONTH FOLLOW-UP
Guo, YiJun
JOURNAL OF UROLOGY, 2020, 203 : E484 - E484
[34] Efficacy of Clozapine in Patients with Schizophrenia - A 3-Month follow-up Study from North India
Singh, Paramvir
Singh, Yesh Chandra
Pandey, Abhinav
Singh, Chitrakshee
Muchhala, Nirali
Karia, Sagar
ANNALS OF INDIAN PSYCHIATRY, 2023, 7 (03) : 203 - 206
[35] Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG
Daniel Subiela, Jose
Rodriguez Faba, Oscar
Aumatell, Julia
Krajewski, Wojciech
Calderon, Julio
Parada, Ruben
Huguet, Jorge
Algaba, Ferran
Breda, Alberto
Palou, Joan
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (01) : 9.e9 - 9.e17
[36] Impact of clinical and pathological subtypes of Carcinoma In Situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG
Subiela Henriquez, J. D.
Rodriguez-Faba, O.
Aumatell, J.
Krajewski, W.
Calderon, J.
Mercade, A.
Balana, J.
Parada, R.
Huguet, J.
Algaba, F.
Breda, A.
Palou, J.
EUROPEAN UROLOGY, 2021, 79 : S988 - S988
[37] Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ
Li, Roger
Shah, Paras H.
Stewart, Tyler F.
Bivalacqua, Trinity
Lamm, Donald L.
Geynisman, Daniel M.
Meeks, Joshua J.
Uchio, Edward M.
Jacob, Joseph M.
Dickstein, Rian J.
Pearce, Shane
Burke, James M.
Steinberg, Gary D.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[38] EFFICACY AND SAFETY OF THREE DIFFERENT TREATMENT REGIMENS IN DE NOVO RENAL TRANSPLANT PATIENTS: MONTH 36 FOLLOW-UP RESULTS OF HERAKLES TRIAL
Hauser, I. A.
Witzke, O.
Arns, W.
Reinke, P.
Sommerer, C.
Neumayer, H. -H.
Guba, M.
Jacobi, J.
Heller, K.
Kliem, V.
Lehner, F.
Baeumer, D.
Porstner, M.
Rath, T.
Zeier, M.
Budde, K.
TRANSPLANT INTERNATIONAL, 2014, 27 : 51 - 51
[39] Efficacy and Safety of Three Different Treatment Regimens in De Novo Renal Transplant Patients: Month 36 Follow-Up Results of HERAKLES Trial
Zeier, M.
Budde, K.
Arns, W.
Guba, M.
Sommerer, C.
Neumayer, H.
Jacobi, J.
Kliem, V.
Huppertz, A.
Porstner, M.
Sieder, C.
Paulus, E.
Witzke, O.
Lehner, F.
TRANSPLANTATION, 2014, 98 : 81 - 82
[40] Phase II/III clinical results of IL-15R[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
Chamie, Karim
Chang, Sam
Gonzalgo, Mark L.
Kramolowsky, Eugene, V
Sexton, Wade J.
Reddy, Sandeep K.
Bhar, Paul
Garner, Chad
Soon-Shiong, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

← 1 2 3 4 5 →